FDA Approves Weltruza (olanzapine) Once-Monthly Subcutaneous Injection for the Treatment of Adults with Schizophrenia
RegulatoryapprovedWeltruzaPositive
AI Analysis
Summary
The FDA approved Teva Pharmaceuticals' Weltruza (olanzapine) once-monthly subcutaneous injection for treating adults with schizophrenia. This regulatory approval represents a market-moving event for the company's psychiatric medication portfolio.
Outcome Details
FDA approved Weltruza (olanzapine) once-monthly subcutaneous injection for treatment of adults with schizophrenia
Importance:8/10
Sentiment:
0.95
FDA approvalschizophreniainjectableonce-monthlypsychiatry
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on October 9, 2026 9:10 PM